Arcellx, Inc. (ACLX) Stock Analysis

Q: What is the ACLX stock price target?

Take-profit $112.83 (-1.9% upside). Prior stop was $114.87.

Q: What are the risks of investing in ACLX?

Target reached (-15.2% upside); Quality below floor (2.0 < 4.0); Value-trap signals (2/5): Margin compression (op margin -123.4%), Material insider selling (5 sells, 0.02% of cap); Target reached (-15.2% upside); Quality below floor (2.0 < 4.0).

Q: Is ACLX overvalued or undervalued?

Arcellx, Inc. trades at a P/E of N/A (forward -66.4). TrendMatrix value score: 3.0/10. Overall verdict: Sell.

Q: What do analysts say about ACLX?

14 analysts cover ACLX with a consensus score of 2.6/5. Average price target: $112.

SellVALUE-TRAP 2/5Moderate ConfidenceUpdated 2 days ago (May 18, 2026, 9:01 PM ET)

Healthcare · Biotechnology

Arcellx is a clinical-stage biotech developing D-Domain powered CAR-T immunotherapies for cancer and autoimmune diseases. Lead product anito-cel (BCMA ddCAR for multiple myeloma) filed BLA with FDA in December 2025; pending acquisition by Gilead at $115 per share plus a $5 CVR... Read more

$115.11-1.9% A.UpsideScore 4.0/10#150 of 157 Biotechnology

QualityF-score3 / 9FCF yield-1.44%

Stop $114.87Target $112.83(resistance)A.R:R -1.0:1

Analyst target$112.20-2.5%10 analysts

$112.83our TP

$115.11price

$112.20mean

$82

$120

Sell if holding. Engine safety override at $115.11: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.0/10, moderate confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

Recent Developments — Arcellx, Inc.

Latest news

Cantor Fitzgerald Suspends Neutral Rating on Arcellx — benzinga Apr 29, 2026 negative
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal — benzinga Apr 7, 2026 neutral

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

Target reached (-15.2% upside)

Quality below floor (2.0 < 4.0)

Value-trap signals (2/5): Margin compression (op margin -123.4%), Material insider selling (5 sells, 0.02% of cap)

Key Metrics

P/E (TTM)—

P/E (Fwd)-66.4

Mkt Cap$6.7B

EV/EBITDA-25.7

Profit Mgn0.0%

ROE-53.4%

Rev Growth-89.2%

Beta0.25

DividendNone

Rating analysts14

Quality Signals

Piotroski F3/9

Options Flow

IV37%normal

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value3.015%0.45

Quality2.015%0.30

Growth5.015%0.75

Momentum6.510%0.65

Sentiment4.310%0.43

Insider Activity3.310%0.33

Peer Rank2.010%0.20

Technical Setup4.35%0.21

Risk Profile9.05%0.45

Catalyst5.45%0.27

Overall (Σ contributions)4.04

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

3.3

Moat

4.0

Current Ratio

8.6

Cash-burning: FCF -436% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

0.9

Quality Rank

2.1

Value Rank

5.0

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Analyst Target

3.0

Expensive valuation

Low model confidence on this dimension (33%).

GatesA.R:R -1.0=NEGATIVEMomentum 6.5>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate

RSI

74 · Overbought

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $114.60Resistance $115.13

Price Targets

$115

$113

A.Upside-2.0%

A.R:R-1.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (-15.2% upside)

! Quality below floor (2.0 < 4.0)

! Value-trap signals (2/5): Margin compression (op margin -123.4%), Material insider selling (5 sells, 0.02% of cap)

Earnings

3/4 beats

Next Earnings2026-05-07 (nulld)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is ACLX stock a buy right now?

Sell if holding. Engine safety override at $115.11: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $114.87. Score 4.0/10, moderate confidence.

What is the ACLX stock price target?

Take-profit target: $112.83 (-1.9% upside). Prior stop was $114.87. Stop-loss: $114.87.

What are the risks of investing in ACLX?

Target reached (-15.2% upside); Quality below floor (2.0 < 4.0); Value-trap signals (2/5): Margin compression (op margin -123.4%), Material insider selling (5 sells, 0.02% of cap).

Is ACLX overvalued or undervalued?

Arcellx, Inc. trades at a P/E of N/A (forward -66.4). TrendMatrix value score: 3.0/10. Verdict: Sell.

What do analysts say about ACLX?

14 analysts cover ACLX with a consensus score of 2.6/5. Average price target: $112.

What does Arcellx, Inc. do?Arcellx is a clinical-stage biotech developing D-Domain powered CAR-T immunotherapies for cancer and autoimmune...